Celltrion Inc (068270) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Celltrion Inc (068270) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH16517D
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on research, development and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, psoriatic arthritis and psoriasis. Its pipeline portfolio spans monoclonal antibody biosmilars for the treatment of rheumatoid arthritis; colorectal cancer; large Intestine Cancer and respiratory disease; and antibody biologics for and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, seasonal influenza antibody; and antibody drug conjugates. Celltrion develops drugs by utilizing its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon city, South Korea.

Celltrion Inc (068270)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Celltrion Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Celltrion Enters into Co- Development Agreement with Yonsei University 12

Celltrion Enters into Development Agreement with Emory University 13

Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14

Teva Pharma Enters into Distribution Agreement with Celltrion 15

Licensing Agreements 16

Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16

Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17

Equity Offering 19

Celltrion Healthcare Raises USD900.7 Million in IPO 19

Debt Offering 20

Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20

Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21

Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22

Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23

Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24

Acquisition 25

Temasek Acquires Additional Stake In Celltrion 25

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26

Celltrion Inc-Key Competitors 28

Celltrion Inc-Key Employees 29

Celltrion Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Legal and Regulatory 31

Sep 18, 2018: Celltrion receives EIR from the FDA 31

Product News 32

05/23/2017: Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra 32

05/18/2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab) 33

02/22/2017: Mundipharma to launch Truxima (rituximab), the first biosimilar monoclonal antibody for the treatment of cancer, in seven European markets 34

02/17/2017: New Data in Crohn's Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA and REMICADE 35

02/17/2017: Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohns Disease 36

Product Approvals 37

May 30, 2018: Celltrion Completes Resubmission for Biosimilar Candidate to FDA for Review 37

Apr 06, 2018: Celltrion Receives CRL from the U.S. FDA for rituximab biosimilar 38

Jun 29, 2017: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab) 39

Clinical Trials 40

Dec 11, 2017: Top UK university hospital unveils data that support the use of rapid infusion for Truxima (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma 40

Nov 05, 2017: Celltrion Healthcare Presents Phase III Switching Data Supporting the Long-Term Efficacy and Safety of Truxima (CT-P10, Biosimilar Rituximab) in Rheumatoid Arthritis Patients 41

Oct 29, 2017: One Year Maintenance And Switching Data In Patients With Crohn's Disease Support The Use Of Inflectra (Infliximab CT-P13) In IBD 42

Jun 14, 2017: Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis 43

May 12, 2017: Celltrion Healthcare: Lancet Publishes Full Data-Set from Influential NOR-SWITCH Study 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celltrion Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Celltrion Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Celltrion Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Celltrion Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Celltrion Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Celltrion Enters into Co- Development Agreement with Yonsei University 12

Celltrion Enters into Development Agreement with Emory University 13

Nippon Kayaku Enters into Agreement with Celltrion Healthcare 14

Teva Pharma Enters into Distribution Agreement with Celltrion 15

Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 16

Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 17

Celltrion Healthcare Raises USD900.7 Million in IPO 19

Celltrion Pharm Raises USD27.1 Million in Public Offering of 1.5% Bonds Due 2019 20

Celltrion Pharm Raises USD46.3 Million in Public Offering of 1.5% Bonds Due 2020 21

Celltrion Pharm Raises USD9.2 Million in Public Offering of 1.5% Bonds Due 2019 22

Celltrion Pharm Raises USD56.6 Million in Public Offering of 1.5% Bonds Due 2018 23

Celltrion Raises USD300 Million Public Offering of 2.75% Bonds Due 2018 24

Temasek Acquires Additional Stake In Celltrion 25

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 26

Celltrion Inc, Key Competitors 28

Celltrion Inc, Key Employees 29

Celltrion Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Celltrion Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com